BiotechTube
Immitra Bio

Immitra Bio

Basel, Switzerland· Est.
immitrabio.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

Immitra Bio is an early-stage biotech developing an innovative cell and gene therapy platform centered on editing hematopoietic stem cells (HSCs) using CRISPR-Cas9. The company targets rare genetic diseases, a space where a significant percentage of patients, many of whom are children, lack any approved therapies. By creating durable, one-time treatments via ex vivo gene editing of HSCs, Immitra aims to address conditions with profound unmet needs. The company is privately held, pre-revenue, and appears to be in the pre-clinical research and platform development stage.

Rare Genetic Diseases

Technology Platform

A genetic medicine platform combining hematopoietic stem cells (HSCs) with CRISPR-Cas9 gene editing to create precise, durable 'living drug' therapies via ex vivo cell engineering.

Opportunities

The high unmet need in pediatric rare genetic diseases presents a compelling market for transformative, one-time therapies.
A successful platform could expand beyond rare diseases into broader indications like HIV or autoimmune disorders.
The Basel ecosystem offers access to world-class research, talent, and life sciences capital.

Risk Factors

The company faces significant scientific risk in proving its HSC editing platform is safe, effective, and manufacturable at scale.
It is a late entrant in a field with well-funded, clinically-advanced competitors.
As a pre-revenue startup, it is entirely dependent on external funding, creating substantial financial and operational risk.

Competitive Landscape

Immitra Bio operates in the highly competitive cell and gene therapy space, directly competing with established players like CRISPR Therapeutics, Intellia Therapeutics, and Beam Therapeutics, which have advanced HSC editing programs already in clinical trials. Differentiation will require demonstrating superior editing efficiency, safety, or targeting novel disease niches not addressed by incumbents.

More companies in Cell & Gene Therapy →More companies in Switzerland →